2022
-1
archive,date,paged,paged-2,date-paged-2,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-5.7,vc_responsive
 

June 2022

Home > 2022 (Page 2)

18 Jun

Posted at 10:30h in Blogs by

The addition of capivasertib to fulvestrant showed a significant PFS benefit in the original pathway-altered and non-altered subgroups. In the pathway altered subgroup, the median OS with the combination was significantly longer than fulvestrant alone. The expanded biomarker testing suggested that capivasertib predominantly benefits patients with PI3K/AKT/PTEN pathway-altered tumours. (Ref: Howell SJ et al.  Lancet Oncol. June 1, 2022)
#oncologyresearch #clinicaldevelopment

https://www.linkedin.com/feed/update/urn:li:activity:6943811898039484416

12 Jun

Posted at 10:45h in Blogs by

In patients with KRASG12C-mutated NSCLC previously treated with platinum-based chemotherapy and checkpoint inhibitor therapy, adagrasib showed an objective response of 42.9%. Tumor shrinkage of any magnitude was observed in 79.5% patients (A). Intracranial tumor shrinkage was also seen (B). The median duration of response was 8.5 months (95% CI 6.2 to 13.8), the median PFS was 6.5 months (95% CI, 4.7 to 8.4) and the median overall survival was 12.6 months (95% CI, 9.2 to 19.2). The results were similar to sotorasib.
(Ref: Jänne PA et al. N Engl J Med. June 3, 2022)
#oncologyresearch #drugdevelopment

https://www.linkedin.com/feed/update/urn:li:activity:6941618273817894912

31 May

Posted at 10:04h in Blogs by

In chemotherapy-naïve, PD-L1-positive (tumour proportion score ≥1%) patients with locally advanced or metastatic NSCLC, tiragolumab plus atezolizumab showed a significant improvement in both objective response rate (ORR) and progression-free survival (PFS), with a stratified hazard ratio 0·57 [95% CI 0·37–0·90], p=0·015.
The combination was well tolerated, with a safety profile similar to that of atezolizumab alone. (Cho BC et al. The lancet Oncology May 13, 2022)
#oncologyresearch #clinicaldevelopment

https://www.linkedin.com/feed/update/urn:li:activity:6937287219028070400

30 Apr

Posted at 10:44h in Blogs by

n patients with newly diagnosed IDH1-mutated AML who were ineligible for intensive induction therapy, Ivosidenib/Azacitidine combination showed significantly longer EFS compared to Azacitidine at a median follow-up of 12.4 months. The median OS was 24.0 months with Ivosidenib/Azacitidine and 7.9 months with Azacitidine. Febrile neutropenia and infections were less frequent with Ivosidenib/Azacitidine than Azacitidine.
(Ref: Montesinos P et al. N Engl J Med. April 21,2022)

#oncologyresearch #drugdevelopment

https://www.linkedin.com/feed/update/urn:li:activity:6926072382784704512

23 Apr

Posted at 10:42h in Blogs by

In patients with platinum-sensitive, recurrent ovarian cancer previously treated with at least two platinum-based regimens, Fuzuloparib as a maintenance therapy showed a significantly improved progression-free survival compared with placebo, regardless of germline BRCA 1/2 mutation. (Ref: Li N et al. J Clin Oncol. April 11, 2022)
#oncologyresearch #clinicaldevelopment

https://www.linkedin.com/feed/update/urn:li:activity:6923581090574000128

16 Apr

Posted at 11:30h in Blogs by

Indolent MCL patients treated with frontline ibrutinib plus rituximab showed an overall response of 84% after 12 cycles of treatment, with 80% of patients experiencing a CR. Undetectable MRD in the peripheral blood was achieved in 87% of patients. The estimated PFS at 36 months was 93%. At 2 years, 69% of patients could discontinue ibrutinib because of undetectable MRD. (Ref: Giné E et al. J Clin Oncol. 2022)
#oncologyresearch

https://www.linkedin.com/feed/update/urn:li:activity:6921011455219646464

01 Apr

Posted at 10:30h in Blogs by

In patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane, the risk of disease progression or death was lower with trastuzumab deruxtecan than trastuzumab emtansine [Hazard ratio – 0.28 (p<0.001)]. The corresponding overall survival rate was 94.1% and 85.9% after 12 months, and the overall response was 79.7% and 34.2%. (Ref: Cortés J, et al. N Engl J Med March 24, 2022).
#oncologyresearch

https://www.linkedin.com/feed/update/urn:li:activity:6915618089447387136

26 Mar

Posted at 10:59h in Blogs by

In patients with relapsed, BRCA1-mutated or BRCA2-mutated ovarian cancer, who received 2 or more lines of prior therapies, Rucaparib showed significantly longer median progression-free survival of 7.4 months compared to 5.7 months with chemotherapy (platinum-based and non-platinum-based chemotherapy). # ARIEL4 study. (Ref: Kristeleit R et al. The lancet Oncology March 14, 2022)
#oncologyresearch

https://www.linkedin.com/feed/update/urn:li:activity:6913402413664104448

 

19 Mar

Posted at 11:53h in Blogs by

Ribociclib plus letrozole showed a significant overall survival benefit as compared with placebo plus letrozole. Median overall survival was 63.9 months (95% CI, 52.4 to 71.0) with ribociclib plus letrozole and 51.4 months (95% CI, 47.2 to 59.7) with placebo plus letrozole (HR for death, 0.76; 95% CI, 0.63 to 0.93; P=0.008).

Front line therapy with the combo improved median overall survival by 1 year compared to letrozole alone.
(Ref: Hortobagyi et al.NEJM March 10, 2022.)

https://www.linkedin.com/feed/update/urn:li:activity:6910855914283540480

11 Mar

Posted at 10:45h in Blogs by

The mechanisms of resistance to noncovalent (reversible) BTK inhibitors was not fully known. Genomic analyses of pre and post-treatment samples from patients with CLL treated with the non-covalent BTK inhibitor pirtobrutinib showed that resistance to noncovalent BTK inhibitors arose through on-target BTK mutations and downstream PLCγ2 mutations. This data suggests new mechanisms of genomic escape from established covalent and novel noncovalent BTK inhibitors. (Ref: Wang E et al.NEJM, 2022)

https://www.linkedin.com/feed/update/urn:li:activity:6907962121779597312